As of 2025-06-16, the Relative Valuation of Akebia Therapeutics Inc (AKBA) is (3.43) USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.56 USD, the upside of Akebia Therapeutics Inc based on Relative Valuation is -196.3%.
The range of the Relative Valuation is (3.30) - (3.69) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 19.1x - 25.1x | 23.1x |
| Forward P/E multiples | 15.7x - 21.4x | 16.6x |
| Fair Price | (3.30) - (3.69) | (3.43) |
| Upside | -192.7% - -203.7% | -196.3% |
| Date | P/E |
| 2025-06-13 | -20.63 |
| 2025-06-12 | -21.16 |
| 2025-06-11 | -20.69 |
| 2025-06-10 | -22.72 |
| 2025-06-09 | -22.20 |
| 2025-06-06 | -23.01 |
| 2025-06-05 | -21.39 |
| 2025-06-04 | -21.10 |
| 2025-06-03 | -19.82 |
| 2025-06-02 | -18.84 |
| 2025-05-30 | -17.56 |
| 2025-05-29 | -17.45 |
| 2025-05-28 | -16.69 |
| 2025-05-27 | -16.92 |
| 2025-05-23 | -16.58 |
| 2025-05-22 | -16.40 |
| 2025-05-21 | -16.29 |
| 2025-05-20 | -16.92 |
| 2025-05-19 | -16.23 |
| 2025-05-16 | -15.13 |
| 2025-05-15 | -14.72 |
| 2025-05-14 | -14.20 |
| 2025-05-13 | -14.37 |
| 2025-05-12 | -14.08 |
| 2025-05-09 | -14.78 |
| 2025-05-08 | -15.19 |
| 2025-05-07 | -14.26 |
| 2025-05-06 | -13.45 |
| 2025-05-05 | -13.56 |
| 2025-05-02 | -14.20 |
| 2025-05-01 | -13.85 |
| 2025-04-30 | -13.97 |
| 2025-04-29 | -14.08 |
| 2025-04-28 | -14.08 |
| 2025-04-25 | -13.79 |
| 2025-04-24 | -13.22 |
| 2025-04-23 | -12.52 |
| 2025-04-22 | -12.40 |
| 2025-04-21 | -12.00 |
| 2025-04-17 | -11.94 |
| 2025-04-16 | -11.01 |
| 2025-04-15 | -10.95 |
| 2025-04-14 | -10.61 |
| 2025-04-11 | -9.56 |
| 2025-04-10 | -8.98 |
| 2025-04-09 | -9.85 |
| 2025-04-08 | -9.74 |
| 2025-04-07 | -10.26 |
| 2025-04-04 | -10.26 |
| 2025-04-03 | -10.90 |